Literature DB >> 7105179

The TATA homology and the mRNA 5' untranslated sequence are not required for expression of essential adenovirus E1A functions.

T F Osborne, R B Gaynor, A J Berk.   

Abstract

Adenovirus E1A encodes a protein that facilitates the transcription of other early viral transcriptional units and is required for virus-induced transformation. To study the function of non-protein-coding DNA sequence at the 5' end of this transcriptional unit, we constructed mutant viruses with deletions in this region. Deletion of sequence just upstream from the TATA homology does not affect the level or sequence of E1A mRNAs. Deletion of the TATA homology decreases the level of E1A mRNAs by a factor of 5-10 and shifts the mRNA 5' ends from the major 5' end found in wild-type transcripts to a set of minor ends found in wild-type E1A mRNAs. This suggests that the TATA homology is required for an efficient transcription initiation mechanism, and that in its absence a less efficient, less precise mechanism is unmasked. Analysis of mRNAs from other early regions establishes that E2 and E3 regions are most dependent on E1A functions for expression of maximal mRNA levels, E4 is less dependent and E1B is the least dependent. Deletion of the TATA homology, a sequence highly conserved among human adenoviruses, and the entire 5' untranslated sequence of the E1A mRNAs decreases neither the rate of virus replication in a host in which E1A expression is required, nor the efficiency of transformation of rat embryo cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105179     DOI: 10.1016/0092-8674(82)90098-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  51 in total

1.  Genetic dissection of the transactivating domain of the E1a 289R protein of adenovirus type 2.

Authors:  M L Fahnestock; J B Lewis
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

2.  Cooperative binding of EF-1A to the E1A enhancer region mediates synergistic effects on E1A transcription during adenovirus infection.

Authors:  J T Bruder; P Hearing
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

3.  Opposite-strand RNAs from the 5' flanking region of the mouse dihydrofolate reductase gene.

Authors:  P J Farnham; J M Abrams; R T Schimke
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc.

Authors:  Kathryn A Tworkowski; Abhishek A Chakraborty; Andrew V Samuelson; Yvette R Seger; Masako Narita; Gregory J Hannon; Scott W Lowe; William P Tansey
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-14       Impact factor: 11.205

5.  cis-dominant defect in activation of adenovirus type 5 E1b early RNA synthesis.

Authors:  C L Parks; D J Spector
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Translational efficiencies of polyomavirus late mRNA molecules that differ in the sequences of their 5' noncoding late leader exons.

Authors:  E Rhee; G G Carmichael
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  An immunodominant domain in adenovirus type 2 early region 1A proteins.

Authors:  A S Tsukamoto; B Ferguson; M Rosenberg; I L Weissman; A J Berk
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

8.  Individual adenovirus type 5 early region 1A gene products elicit distinct alterations of cellular morphology and gene expression.

Authors:  B E Roberts; J S Miller; D Kimelman; C L Cepko; I R Lemischka; R C Mulligan
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

9.  Far upstream sequences are required for efficient transcription from the adenovirus-2 E1A transcription unit.

Authors:  P Sassone-Corsi; R Hen; E Borrelli; T Leff; P Chambon
Journal:  Nucleic Acids Res       Date:  1983-12-20       Impact factor: 16.971

10.  Local character of readthrough activation in adenovirus type 5 early region 1 transcription control.

Authors:  Li Shen; David J Spector
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.